A review on development of MUC1-based cancer vaccine
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Mucin 1 (MUC1) is a transmembrane mucin glycoprotein expressed on the surface of almost all epithelial cells. Aberrantly glycosylated MUC1 is associated with cellular transformation from a normal to malignant phenotype in human cancers. Therefore, MUC1 is the major target for the design and development of cancer vaccines. MUC1-based cancer vaccines are a promising strategy for preventing cancer progression and metastasis. This review summarizes the most significant milestones achieved to date in the development of different MUC-1-based vaccine approaches in clinical trials. Further, it provides perspectives for future research that may promote clinical advances in infection-associated cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust immune responses elicited by a fully synthetic three-component vaccine
Ingale, S., Wolfert, M. A., Gaekwad, J., Buskas, T., & Boons, G.-J. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.25 · Cited by 337
Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines
Hossain, M., & Wall, K. (2016) · Vaccines · doi:10.3390/vaccines4030025 · Cited by 74
Scheid, E., Major, P., Bergeron, A., Finn, O. J., Salter, R. D., Eady, R., Yassine-Diab, B., Favre, D., Peretz, Y., Landry, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0189 · Cited by 72
Cited by
Guerreiro, A., Compañón, I., Lazaris, F. S., Labão‐Almeida, C., Oroz, P., Ghirardello, M., Marques, M. C., Corzana, F., & Bernardes, G. J. L. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202411009 · Cited by 28
Koeneman, B. J., Schreibelt, G., Gorris, M. A. J., Hins - de Bree, S., Westdorp, H., Ottevanger, P. B., & de Vries, I. J. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368103 · Cited by 24
“In this study we loaded cDC2s and pDCs with PepTivators covering the complete proteins Mucin-1 and Survivin, known immunogenic EC targets (21 – 24).”
MethodCell Therapy as Target Therapy against Colon Cancer Stem Cells
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098163 · Cited by 24
Bermejo, I. A., Guerreiro, A., Eguskiza, A., Martínez-Sáez, N., Lazaris, F. S., Asín, A., Somovilla, V. J., Compañón, I., Raju, T. K., Tadic, S., et al. (2024) · JACS Au · doi:10.1021/jacsau.3c00587 · Cited by 18
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14
“MUC1 with abnormal glycosylation is a well-recognized TSA on epithelial cell tumors (76).”
Metadata
- Authors
- Gao, T., Cen, Q., & Lei, H.
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 132
- Pages
- 110888
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W3093730945
- Cited by
- 151
- References
- 3
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review on development of MUC1-based cancer vaccine. https://app.cochat.ai/papers/10.1016/j.biopha.2020.110888
- The paper
- Gao, T., Cen, Q., & Lei, H. (2020). A review on development of MUC1-based cancer vaccine. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2020.110888
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.